
Blood Clots and the Johnson & Johnson Vaccine: What We Know So Far
Infectious disease physician-scientist Wilbur Chen discusses the rare cases of blood clots linked to the immunization
Infectious disease physician-scientist Wilbur Chen discusses the rare cases of blood clots linked to the immunization
For the first time, a randomized controlled trial shows the psychedelic offers potent, if short-term, relief in comparison with an SSRI
An infectious disease doctor answers questions about the CDC’s and FDA’s decision to pause the vaccine’s use over a possible link with blood clots
Researchers are searching for possible links between unusual clotting and the Oxford-AstraZeneca coronavirus vaccine
Pulmonary fibrosis is diagnosed in about 50,000 new patients annually, and as many as 40,000 Americans die from it each year
The pandemic has spotlighted ways to make clinical trials easier on patients and better for science, a heart drug researcher says
Reactions reflect unique features of an individual’s immune system, not the strength of a response
Scientific American talked to scientists about everything from what efficacy means to protection against the new coronavirus variants
Willingness is rising, even among skeptical groups, at a time when there are still not enough doses to go around
Uptake by patients and physicians has been low in the U.S. even though some therapies have been authorized for months
Trials of all three vaccines came up with different efficacy numbers, but all offer crucial protection in this health emergency
Trusted messengers and repeated reminders can overcome hesitancy, social science shows
Vaccine makers are designing follow-up shots based on new mutations to keep the disease at bay
As more coronavirus vaccines are rolled out, researchers are learning about the extent and nature of side effects
Antibiotics abound, but virus-fighting drugs are harder to come by. Fortunately, scientists are getting better at making and finding them
Some evidence indicates that short waits are safe, but there is a chance that partial immunization could help risky new coronavirus variants to develop
The scantness of available data leaves the decision up to the individual and their doctors, though benefits can outweigh risks in some cases
It will not be an easy task
After Pfizer and Moderna, a slew of other candidates could fill gaps in efficacy, production or distribution
Lessons from other viruses show that even if vaccines don’t completely stop disease spread, they can still successfully contain it
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account